Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.
Chinese digital healthcare platform inCarey has raised $30 million in an extended tranche of Series B funding from Long Hill Capital.
Investcorp has acquired minority stakes in two Chinese healthcare companies – hospital operator Lu Daopei Medical Group and telemedicine platform WeDoctor – paying undisclosed sums.
GemPharmatech, a Chinese company that provides genetically-modified mice for use in drug tests, has raised RMB400 million ($58.6 million) Series B led by GL Ventures, the VC arm of Hillhouse Capital.
Bain Capital has agreed to acquire Japanese pharmacy chain store operator Kirindo Holdings through a tender offer that values the business at JPY39.7 billion ($374 million).
DCP Capital Partners has acquired a 9% stake in Tonghua Dongbao Pharmaceutical, a Chinese pharmaceutical company specializing in diabetes treatment, for RMB1.94 billion ($283.7 million).
LinkDoc Technology, a Chinese healthcare big data company, has raised RMB700 million ($102 million) in an extended Series D round from CICC Capital, Youshan Capital, and iFOF, a fund-of-funds launched by CBC Capital and the Tianjin government.
Oncocross, a South Korean drug developer that uses artificial intelligence (AI) to identify new applications for treatments already in clinical trials, has raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate Investment and GNTech...
Ennovation Ventures, a Chinese life sciences and healthcare-focused investor, and China Growth Capital have led a RMB130 million ($19 million) round for local biotech developer InxMed.
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
SoftBank Vision Fund has led a $100 million Series C round for Biofourmis, a Singapore founded and now US-based operator of a health analytics platform.
Creador's $34 million investment in packaging supplier Shriji Polymers represents an indirect bet on India's growing pharmaceutical industry. Product development and capacity expansion are priorities
Shukun sought to differentiate itself from other Chinese artificial intelligence medical imaging start-ups by focusing on heart rather than lung conditions, but a COVID-19 diagnosis solution has given the company real traction
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised nearly $100 million in Series C round led by Hong Kong-listed contrast research organisation (CRO) Tigermed and Shanghai-based Yingke PE.
The Carlyle Group has paid about $260 million for a 5% stake in Shenzhen-listed Salubris Pharmaceutical.
Creador has invested INR2.5 billion ($34 million) in Shriji Polymers India, a manufacturer of plastic pharmaceuticals packaging, taking a significant minority stake and providing an exit for Tata Capital.
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the medical imaging diagnosis, has raised RMB200 million in the third tranche of Series B round.
BGH Capital and Ontario Teachers’ Pension Plan (OTPP), which recently terminated an acquisition of New Zealand dentistry chain Abano, have renewed their bid at a lower price.
Connect Biopharma, a drug developer based in China and the US, has raised $115 million in Series C funding led by RA Capital Management.
Japan’s Takeda Pharmaceutical has agreed to sell a portfolio of over-the-counter (OTC) medicines and health products to The Blackstone Group for JPY242 billion ($2.3 billion).
Sanjay Kukreja, managing partner at India-focused ChrysCapital Partners, discusses timing, healthcare, technology, and why it makes sense to back entrepreneurs you’ve backed before
Shuidi, a China-based insurance technology platform also known as Waterdrop, has raised $230 million in Series D funding jointly led by Tencent Holdings and Swiss Re Group. Existing investors IDG Capital and Wisdom Choice Global Fund re-upped.